{
  "id": 16792816,
  "title": "Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die",
  "url": "https://urgent.news/2026/10/27/artiva-axes-94-of-workforce-weighs-strategic-alternatives-after-two",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-27T19:30:41.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/translational-medicine/artiva-axes-94-of-workforce-weighs-strategic-alternatives-after-two-patients-in-phase-iia-trial-die/"
  },
  "original_language": "en",
  "account": "Artiva Biotherapeutics has announced it will slash its workforce by 94%, or approximately 98 employees out of a total of 104, and reassess strategic options following the deaths of two patients in a Phase IIa trial for its lead candidate, AlloNK®. The deaths occurred in a study evaluating AlloNK in combination with rituximab, a treatment for arthritis and cancer, in rheumatoid arthritis, Sjögren's Disease, idiopathic inflammatory myopathies, and systemic sclerosis. One patient died from a neurological condition likely related to a chemotherapy drug used in the trial, while the other's cause of death remains undetermined. Artiva will pause enrollment and dosing for both a Phase IIa and a Phase III trial of AlloNK, as well as cancel plans to present clinical data at an upcoming conference. The company cited uneven clinical data, assessment of risks and benefits, and potential enrollment delays as reasons for the decision, which also included an assessment of the therapy's overall development and commercial outlook.",
  "summary": "In announcing the layoffs and strategic alternatives review, Artiva disclosed that two patients in the trial who underwent the study treatment died in Grade 5 safety events. One patient succumbed to leukoencephalopathy while the second experienced sudden death. The post Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die appeared first on GEN -…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}